Evidence map›Paper›PMID 25511320›Full record

Trial reportMedical oncology (Northwood, London, England)2015

Evaluation of urinary miRNA-96 as a potential biomarker for bladder cancer diagnosis.

Sanaa Eissa, Haidy Habib, Esraa Ali, Yossif Kotb

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Schistosomiasis and Bladder Cancer in Egypt: Truths and Myths.Open access Macedonian journal of medical sciences · 2019
    Article
  8. MicroRNAs: Key Players in Bladder Cancer.Molecular diagnosis & therapy · 2019
    Review
  9. Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer.International journal of molecular sciences · 2019
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sanaa EissaDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, dr_sanaa_eissa@yahoo.com.
Haidy Habib
Esraa Ali
Yossif Kotb
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For bladder cancer, a new diagnostic marker is needed to avoid painful cystoscopy. The aim of this study was to explore the efficacy of urinary miRNA-96 as molecular marker in bladder cancer diagnosis and its relation to bilharziasis. Urine cytology, serologic assessment of schistosomiasis and estimation of miRNA-96 by real-time PCR were carried out for 94 bladder cancer patients, 30 benign bladder lesions and 60 healthy individuals. Expression of miRNA-96 showed a significant difference among the three tested groups and also between benign and malignant bilharzial cases. Urinary miRNA-96 is a good noninvasive diagnostic biomarker for bladder cancer.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorChildHumansMicroRNAsMiddle AgedReal-Time Polymerase Chain ReactionSchistosomiasisUrinary Bladder NeoplasmsYoung AdultBiomarkers, TumorMicroRNAsMIRN96 microRNA, human

Identifiers

PMID25511320
OpenAlexW2036307656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.